cjc-1295 ipamorelin cancer risk studies + Some peptides can be risky – risk of injecting too much

due to sustained GH elevation) Injection site reactions Headache Flushing Tingling or numbness in hands and feet (carpal tunnel-like symptoms at higher doses) Increased appetite Joint stiffness (if GH levels become too high) CJC-1295 without DAC (Mod GRF 1-29) Injection site reactions Flushing (more common than with DAC due to acute release pattern) Headache Mild dizziness Less water retention than DAC form Semaglutide Side Effect Profile Nausea (most common, dose-dependent) Vomiting Diarrhea or constipation Abdominal pain Decreased appetite (therapeutic effect) Fatigue Injection site reactions Combined Side Effect Analysis When evaluating additive side effect risk: GI symptoms: Come exclusively from semaglutide

One hypothesis is that GHRP-6 and GHRP-2 have off-target activity at corticotroph cells or hypothalamic CRH neurons that ipamorelin lacks due to its modified structure

Requires monitoring but well-characterized

In human clinical trials, SS31 showed favorable safety and tolerability profiles with no doselimiting toxicities [4][5]

Integrated Wellness for Maximized Results Our integrated wellness focus recognizes that GH optimization works best when other systems are balanced